FOSUN PHARMA (02196.HK) Financial Statements - Balance Sheet/Income Statement/Cash Flow

Event Tracking

Dec23

Fosun Pharma Aims to Acquire 75% Equity of Green Valley Pharmaceutical for 1.412 Billion Yuan

19:12

Fosun Pharma Acquires Green Valley Pharmaceuticals Controlling Stake and Supports Clinical Trials for Gantenerumab Capsules

00:07

Fosun Pharma Discloses Sales Data and Clinical Trial Progress of 971

00:01

Dec19

Fosun Pharma Aims to Acquire Green Valley for Continued Clinical Trials of 'Nine-Seven-One'

00:18

Dec18

Fosun Pharmaceutical Industry Co., Ltd. signs Cooperation and Option Agreement with ClavisBio

10:22

Dec17

Fosun Pharmaceutical Plans to Invest in Green Valley to Advance Clinical Trials of 971 Drug

04:42

Schedules & Filings

Schedules

Filings

Oct28

Earning Release(CST)

FY2025 Q3 Earning Release (HKD) Revenue 10.8 B, Net Income 897.85 M, EPS 0.3388

Aug26

Earning Release(CST)

FY2025 Q2 Earning Release (HKD) Revenue 11.05 B, Net Income 1.026 B, EPS 0.3825

Aug22

Distribution Plan(CST)

Cash dividend 0.35 HKD

Stock List

Top Gainers

Top Decliners

Main Board

Symbol

Price

%Chg

Change